Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2 (RP2)
| Registry | NCT03012217, acronym RP2 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 1612 (Actual) |
| Sponsor | BioFire Diagnostics, LLC (Industry) |
| Conditions | Upper Resp Tract Infection |
| Interventions | Observational Study (Other) |
| Dates | start 2016-09-01, primary completion 2016-12-01, completion 2016-12-01, first posted 2017-01-06, last updated 2017-01-12 |
| Locations | 3 sites in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Upper Resp Tract Infection All trials of Observational Study
This is a performance study to test the sensitivity and specificity of the BioFire FilmArray Respiratory Panel (RP) 2. The purpose of this study is to prospectively collect and test residual NPS specimens and generate performance data to support regulatory classification of the FilmArray RP2 as an in vitro diagnostic (IVD) in the US, European Union (EU), Canada, and other regions.
The FilmArray Respiratory Panel 2 (RP2) is an automated sample-to-answer PCR-based diagnostic for the identification of common upper respiratory viral and bacterial pathogens in nasopharyngeal swab (NPS) specimens collected in viral transport media (VTM). The purpose of this study is to prospectively collect and test residual NPS specimens and generate performance data to support regulatory classification of the FilmArray RP2 as an in vitro diagnostic (IVD) in the US, European Union (EU), Canada, and other regions.
Clinical performance evaluations will be initiated at sites in the US and/or EU during the 2016/2017 respiratory illness season, approximately September through December.Prior to performing the prospective clinical evaluation, each participating site will have the necessary Institutional Review Board (IRB) reviews (or equivalent for non-U.S. sites).
Specimens for inclusion in this study will be residual, de-identified NPS collected in VTM leftover from clinician-ordered respiratory pathogen testing.
Comparator testing will be performed using de-identified specimen aliquots at a central reference laboratory.
This study is funded by BioFire Diagnostics, LLC. The FilmArray device conforms to the requirements of the European Union In Vitro Diagnostic Directive (IVDD). This study was designed such that every precaution has been taken to protect the health and safety of patients, users, and other persons.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Specimens that meet inclusion criteria | Other: Observational Study |
Sex: All
Inclusion Criteria: * Specimen is residual NPS in VTM left over from standard of care testing under clinician order for respiratory pathogen analysis * Specimen has been held at appropriate temperature * Sufficient volume remaining after standard of care testing and available for use in the study Exclusion criteria: * Specimen other than NPS in VTM (e.g. nasopharyngeal aspirate, anterior or midturbinate swab, oropharyngeal swab, NPS collected in medium other than VTM) * Specimen cannot be tested within the defined storage parameters * Insufficient specimen volume for testing
| Facility | City | Country | Status |
|---|---|---|---|
| Loyola University Medical Center | Maywood, Illinois | United States | |
| Nationwide Children's Hospital | Columbus, Ohio | United States | |
| Primary Children's Hospital | Salt Lake City, Utah | United States |